The prevalence of gastric cancer (GC) remains high, and its management continues to be a significant challenge. This 2024 literature review focuses on the prognosis and treatment of GC, emphasizing the importance of multidisciplinary approaches. Surgery remains the primary treatment option, but immunotherapy and therapeutic targeting are gaining prominence. Post-surgery, a multidisciplinary approach involving nutritionists and psychologists is crucial. New experimental diagnostic methods, such as spectral CT and diffusion-weighted MRI, have shown promise in predicting response to neoadjuvant chemotherapy. Blood biomarkers like ALDH3B1 and C-reactive protein-to-albumin ratio are potential tools for predicting surgical outcomes and recurrence. Immunological indicators, including Th2 immune responses and markers like ITGA11, play a significant role in prognosis and treatment planning. Chemotherapy options are evolving, with new combinations showing moderate effectiveness. Robotic surgery is being explored for its potential benefits in certain patient populations. Therapeutic targets, such as PFDN5, IGF2BP3, and YY1, are being investigated to improve patient outcomes. The integration of artificial intelligence and traditional diagnostic methods is expected to enhance the accuracy and efficiency of GC management. Despite these advancements, funding for research in diagnosis, prognosis, and treatment remains essential to address the high mortality rate associated with GC.The prevalence of gastric cancer (GC) remains high, and its management continues to be a significant challenge. This 2024 literature review focuses on the prognosis and treatment of GC, emphasizing the importance of multidisciplinary approaches. Surgery remains the primary treatment option, but immunotherapy and therapeutic targeting are gaining prominence. Post-surgery, a multidisciplinary approach involving nutritionists and psychologists is crucial. New experimental diagnostic methods, such as spectral CT and diffusion-weighted MRI, have shown promise in predicting response to neoadjuvant chemotherapy. Blood biomarkers like ALDH3B1 and C-reactive protein-to-albumin ratio are potential tools for predicting surgical outcomes and recurrence. Immunological indicators, including Th2 immune responses and markers like ITGA11, play a significant role in prognosis and treatment planning. Chemotherapy options are evolving, with new combinations showing moderate effectiveness. Robotic surgery is being explored for its potential benefits in certain patient populations. Therapeutic targets, such as PFDN5, IGF2BP3, and YY1, are being investigated to improve patient outcomes. The integration of artificial intelligence and traditional diagnostic methods is expected to enhance the accuracy and efficiency of GC management. Despite these advancements, funding for research in diagnosis, prognosis, and treatment remains essential to address the high mortality rate associated with GC.